Multi-modal shape memory polymers

Information

  • Patent Grant
  • 9308293
  • Patent Number
    9,308,293
  • Date Filed
    Thursday, February 5, 2015
    9 years ago
  • Date Issued
    Tuesday, April 12, 2016
    8 years ago
Abstract
The present disclosure relates to a multi-modal shape memory polymer material comprising a blend or at least one polymer component having a first molecular weight and at least a second polymer component having a second molecular weight that is less than the first component.
Description
BACKGROUND

1. Field of the Invention


This present disclosure relates generally to shape memory polymers and, more particularly, multi-modal shape memory polymers.


2. Related Art


Amorphous orientated shape memory polymers containing single molecular weight distributions are known to relax and form fixation devices when placed into a bone cavity. Upon observation, these shape memory polymer materials relax and try to flow into the small pores of bone. Polymers used for current shape memory applications have molecular weight distributions of polydispersity in the range of between about 2 to about 4. These types of ranges may limit the ability of the polymer to penetrate into the bone, the mechanical properties of the polymer itself, or in the case where the polymer is resorbable, the degradation time of the polymers.


SUMMARY

In an aspect, the present disclosure relates to a multi-modal shape memory polymer material comprising a blend of at least one polymer component having a first molecular weight and at least a second polymer component having a second molecular weight that is less than the first component. In an embodiment, the polymer material is bi-modal. In another embodiment, the first molecular weight has an Mn in excess of about 30,000 Daltons and the second molecular weight has an Mn of up to about 30,000 Daltons. In yet another embodiment, the first molecular weight has an Mn of between about 50,000 and about 1,000,000 Daltons and the second molecular weight has an Mn of between about 2,000 and about 30,000 Daltons. In a further embodiment, the at least one polymer component comprises about 80% of the polymer blend and the second polymer component comprises about 20% of the polymer blend.


In an embodiment, the at least one polymer component and the second polymer component are both resorbable. In another embodiment, the at least one polymer component and the second polymer component are both non-resorbable. In yet another embodiment, one of the at least one polymer component and the second polymer component is resorbable and one of the at least one polymer component and the second polymer component is non-resorbable. In a further embodiment, both of the components are miscible. In yet a further embodiment, the material includes a filler selected from a group consisting essentially of hydroxyapatite, calcium carbonate, and tricalcium phosphate.


In an embodiment, the material includes a porogen selected from a group consisting essentially of sodium chloride, lithium bromide, lithium iodide, calcium chloride, sodium iodide, magnesium sulphate, and calcium sulphate. In another embodiment, at least one or both of the at least one polymer component and the second polymer component includes a polyester selected from a group including P(L)LA, poly (D) lactic acid (P(D)LA), poly (DL) lactic acid (P(DL)LA), poly(L-co-DL) lactic acid (P(LDL)LA), poly (L) lactic acid-co-glycolide (P(L)LGA)), poly (DL) lactic acid-co-glycolide (P(DL)LGA)),poly (D) lactic acid-co-glycolide (P(D)LGA)), polycaprolactone (PCL), PGA, and combinations thereof.


In yet another embodiment, at least one or both of the at least one polymer component and the second polymer component includes a polyacrylate. In a further embodiment, at least one or both of the at least one polymer component and the second polymer component includes a polymethyl methacrylate polymer or copolymer thereof. In yet a further embodiment, at least one or both of the at least one polymer component and the second polymer component includes a polybutyl methacrylate polymer or copolymer thereof. In an embodiment, at least one or both of the at least one polymer component and the second polymer component includes a polybutyl methacrylate-co-polymethyl methacrylate copolymer. In another embodiment, at least one or both of the at least one polymer component and the second polymer component includes a polystyrene copolymer.


In another aspect, the present disclosure relates to an article comprising a multi-modal shape memory polymer material comprising a blend of at least one polymer component having a first molecular weight and at least a second polymer component having a second molecular weight that is less than the first component. The article is selected from a group consisting essentially of rods, pins, nails, screws, plates, anchors, and wedges.


In a further aspect, the present disclosure relates to the use of the article as a fixation device suitable for implantation into bone wherein upon implanting the article into bone and providing the article with energy, the material flows into pores of the bone thereby enhancing fixation of the article to bone.


In yet a further aspect, the present disclosure relates to an article comprising a multi-modal shape memory polymer material comprising a blend of at least one polymer component having a first molecular weight and at least a second polymer component having a second molecular weight that is less than the first component, wherein upon implanting the article into bone and providing the article with energy, the material flows into pores of the bone thereby enhancing fixation of the article to bone.


Further features, aspects, and advantages of the present disclosure, as well as the structure and operation of various embodiments of the present disclosure, are described in detail below with reference to the accompanying drawings.





BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings, which are incorporated in and form a part of the specification, illustrate the embodiments of the present disclosure and together with the description, serve to explain the principles of the disclosure. In the drawings:



FIG. 1 is an overlayed chromatograph showing the molecular weight profile distribution of a monomodal polymer material and the multi-modal polymer material of the present disclosure.



FIG. 2 is a chromatograph showing the molecular weight profile distribution of the multi-modal polymer material of the present disclosure.





DETAILED DESCRIPTION OF THE EMBODIMENTS

The following description of the preferred embodiment(s) is merely exemplary in nature and is in no way intended to limit the disclosure, its application, or uses.


The present disclosure relates to a multi-modal shape memory polymer material comprising a blend of at least one polymer component having a first molecular weight and at least a second polymer component having a second molecular weight that is less than the first component.


The first polymer component represents about 80% of the polymer blend and includes a high molecular weight having an Mn in excess of about 30,000 Daltons, and in some embodiments, between about 50,000 and about 1,000,000 Daltons. The second component represents about 20% of the polymer blend and includes a low molecular weight having an Mn of up to about 30,000 Daltons, and in some embodiments, between about 2,000 and about 30,000 Daltons. The high molecular weight of the first component provides the blend with the necessary mechanical strength and the low molecular weight of the second component provides the blend with the necessary flow characteristics and therefore the necessary amount of integration of the blend into bone, as will be further described below.


For the purposes of this disclosure, both the first and second polymer components include a polylactide based shape memory polymer. However, the polymer material may include a resorbable and/or non-resorbable polymer material having shape memory qualities and which is selected from a group that includes an amorphous polymer, a semi-crystalline polymer, and combinations thereof.


Specific polymers that may be used include polyacrylic/polyacrylate, polymethyl methacrylate (PMMA), polyethyl methacrylate (PEMA), polybutylacrylate, polybutylmethacrylate, polystyrene, poly-alpha-hydroxy acids, polycaprolactones, polydioxanones, polyesters, polyglycolic acid, polyglycols, polylactides, polyorthoesters, polyphosphates, polyoxaesters, polyphosphoesters, polyphosphonates, polysaccharides, polytyrosine carbonates, polyurethanes, and copolymers or polymer blends thereof. Also, the polymer components may be miscible and capable of forming a substantially uniform blend. Polyesters that may be used include P(L)LA, poly (D) lactic acid (P(D)LA), poly (DL) lactic acid (P(DL)LA), poly(L-co-DL) lactic acid (P(LDL)LA), poly (L) lactic acid-co-glycolide (P(L)LGA)), poly (DL) lactic acid-co-glycolide (P(DL)LGA)),poly (D) lactic acid-co-glycolide (P(D)LGA)), polycaprolactone (PCL), PGA, and combinations thereof.


Generally, polymers that display shape memory qualities show a large change in modulus of elasticity at the glass transition temperature (T). The shape-memory function can be achieved by taking advantage of this characteristic. Namely, the mixture of the first and second polymer components is processed, via processes known to one of skill in the art, to make an article having a definite shape (the original shape). The article is then processed to give the article a secondary shape and to provide the article with shape memory qualities. The process may process include, without limitation, die drawing, zone drawing, hydrostatic extrusion, compression flow molding, thermoforming, rolling, and roll drawing,. The article is then softened by providing the article with energy and heating to a temperature (Tr) higher than the Tg of the polymer, but lower than the melting temperature (Tm) thereof so as to deform the article back to its original shape.


The article may include fixation devices, such as, without limitation, rods, pins, intramedullary nails, bone screws, locking screws, plates, anchors, staples, and wedges, for use in the repair of bone and soft tissue. In addition, the article may include a sleeve of polymer material, including a central channel, which allows the sleeve to be placed on a fixation device, such as the fixation devices listed above, for subsequent use in fixating the fixation device to bone, as is described in PCT International Application No. PCT/US08/56828, the disclosure of which is incorporated herein by reference in its entirety.


Examples of adding energy to the polymer material include electrical and thermal energy sources, the use of force, or mechanical energy, and/or a solvent. The thermal energy source may include a heated liquid, such as water or saline. It is also within the scope of this disclosure that once the macroscopic body is placed in the bone, body heat would be transferred from blood and tissue, via thermal conduction, to provide the energy necessary to deform the shape memory polymer material. In this instance, body temperature would be used as the thermal energy source. Examples of electrical energy sources include heat generating devices such as a cauterizing device or insulated conductor, as more fully described in the '828 application, or a heating probe, as more fully described in PCT Application No. PCT/US2008/056836, the disclosure of which is incorporated herein by reference in its entirety.


Any suitable force that can be applied either preoperatively or intra-operatively can be used. One example includes the use of ultra sonic devices, which can relax the polymer material with minimal heat generation. Solvents that could be used include organic-based solvents and aqueous-based solvents, including body fluids. Care should be taken that the selected solvent is not contra indicated for the patient, particularly when the solvent is used intra-operatively. The choice of solvents will also be selected based upon the material to be relaxed. Examples of solvents that can be used to relax the polymer material include alcohols, glycols, glycol ethers, oils, fatty acids, acetates, acetylenes, ketones, aromatic hydrocarbon solvents, and chlorinated solvents.


The article may include a composite or matrix having reinforcing material or phases such as glass fibers, carbon fibers, polymeric fibers, ceramic fibers, ceramic particulates, rods, platelets, and fillers. The fillers may include osteoconductive materials and/or biological actives such as, without hydroxyapatite, calcium carbonate, and tricalcium phosphate. Other reinforcing material or phases known to one of ordinary skill in the art may also be used. In addition, the polymeric material may be made porous via the use of porogens. The porogens include, without limitation, sodium chloride, lithium bromide, lithium iodide, calcium chloride, sodium iodide, magnesium sulphate, and calcium sulphate. Porosity may allow infiltration by cells from surrounding tissues, thereby enhancing the integration of the material to the tissue.


Also, one or more active agents may be incorporated into the material.


Suitable active agents include bone morphogenic proteins, antibiotics, anti-inflammatories, angiogenic factors, osteogenic factors, monobutyrin, thrombin, modified proteins, platelet rich plasma/solution, platelet poor plasma/solution, bone marrow aspirate, and any cells sourced from flora or fauna, such as living cells, preserved cells, dormant cells, and dead cells. It will be appreciated that other bioactive agents known to one of ordinary skill in the art may also be used. Preferably, the active agent is incorporated into the polymeric shape memory material, to be released during the relaxation or degradation of the polymer material. Advantageously, the incorporation of an active agent can act to combat infection at the site of implantation and/or to promote new tissue growth.


EXAMPLE

A bimodal polymer blend, as described above, was prepared by compounding a mixture containing 35% w/w CaCO3, 6.5% w/w Poly(DL-Lactide) (PDLA) (molecular weight, Mn=13900, Mw=20500) and 58.5% w/w Poly(L-co-DL-Lactide) 70:30 (PLDLA) (molecular weight, Mn=354700, Mw=854500) using a twin screw extruder. The resulting material was moulded to produce a 30 mm diameter rod suitable for die drawing. The rod was drawn through a 15 mm die at 75° C. at a rate of 20 mm/minute to produce a rod with a diameter of about 15 mm. The rod included shape memory qualities. The resulting rod was machined to produce plugs of 25 mm in length and 13 mm in diameter. Each plug also included an 8 mm diameter central opening. A stainless steel sleeve having a 4 mm diameter central opening was then press fitted into the central opening of each plug. The sleeve had a length of 25 mm and a diameter of 13 mm.


A monomodal polymer blend, to be used for control purposes, was prepared by compounding a mixture containing 35% w/w CaCO3, 65% w/w Poly(L-co-DL-Lactide) 70:30 (PLDLA) (molecular weight, Mn=354700, Mw=854500) using a twin screw extruder. The resulting material was molded to produce a 30 mm diameter rod suitable for die drawing. The rod was drawn through a 15 mm die at 75° C. at a rate of 20 mm/minute to produce a rod with a diameter of approximately 15 mm. The rod included shape memory qualities. Each plug also included an 8 mm diameter central opening. A stainless steel sleeve having a 4 mm diameter central opening was then press fitted into the central opening of each plug. The sleeve had a length of 25 mm and a diameter of 13 mm.


The molecular weight of both the monomodal and the bimodal polymer blends was determined using gel permeation chromatography (GPC). Table 1 provides the molecular weights of the monomodal and bimodal polymer plugs.














TABLE I








Molecular
Molecular
Polydisperity



Material
weight (Mn)
weight (Mw)
(Mw/Mn)





















Monmodal
97200
244700
2.6



Bimodal
101200
426700
4.2










Additionally, FIGS. 1 and 2 show the molecular weight profile distributions of the monmodal and the bimodal polymer plugs. Specifically, FIG. 1 is an overlayed chromatograph showing graphs 1,2 for both the monomodal polymer plug and the bimodal polymer plug, respectively, and FIG. 2 is a chromatograph showing only the graph 2 for the bimodal polymer plug. The first peak 2a represents the high molecular weight PLLA-co-DL material and the second peak 2b represents the low molecular weight PDLA material.


Samples of the monomodal and the bimodal plugs, described above, were placed into 14 mm diameter sawbone cavities. Each plug was heated for 15 min at 175° C. using a 4 mm diameter heating probe. In order to heat the plugs, the probe was inserted into the central opening of the stainless steel rods. The plugs were then allowed to cool after which the fixation force was measured using the following procedure:


Each sample of sawbone was placed on a cylindrical support on an Instron 5566 test machine. A rigid metal probe of 8 mm diameter, connected rigidly to a 10 kN load cell, was pressed against the one end of each of the plugs at 2 mm/min. The maximum force to push out the plug in each case was recorded and is shown in Table 2 below.











TABLE 2







Push out force (N)



















Bimodal plug




1
2148



2
2265



3
2880



Mean
2431 (+/−393)



Monomodal plug




 375




 460



Mean
 417 (+/−43)










Hence it can be concluded that a multi-modal polymer composition having shape memory qualities contains substantially enhanced mechanical properties compared to a monomodal shape memory polymer composition. it is believed that the enhanced mechanical properties are due to the combination of the high strength high molecular weight polymer and the flow characteristics of the low molecular weight polymer. Specifically, due to the miscibility of the polymer components, it is believed that the lower molecular weight polymer component plasticizes the higher molecular weight component. This aids flow of the multi-modal material into pores of the bone, and hence, fixation of the plug to the bone, thereby providing the plug with enhanced mechanical properties.


For the purposes of this disclosure, a multi-modal polymer composition is a polymer composition having inure than one molecular weight distribution. The multi-modal composition used in this disclosure has two molecular weight distributions (bimodal), however, polymer compositions having more than two molecular weight distributions are also within the scope of this disclosure. In addition, although for the purposes of this disclosure the low molecular weight component is present at about 20% and the high molecular weight component is present at about 80%, the components may be present in any suitable proportions to give the desired increase in strength and flowability. Furthermore, the polymer blend of the present disclosure may be present as a homopolymer blend or as a co-polymer blend.


In view of the foregoing, it will be seen that the several advantages of the disclosure are achieved and attained.


The embodiments were chosen and described in order to best explain the principles of the disclosure and its practical application to thereby enable others skilled in the art to best utilize the disclosure in various embodiments and with various modifications as are suited to the particular use contemplated.


As various modifications could be made in the constructions and methods herein described and illustrated without departing from the scope of the disclosure, it is intended that all matter contained in the foregoing description or shown in the accompanying drawings shall be interpreted as illustrative rather than limiting. Thus, the breadth and scope of the present disclosure should not be limited by any or the above-described exemplary embodiments, but should be defined only in accordance with the following claims appended hereto and their equivalents.

Claims
  • 1. A method for making a bone implant comprising: preparing a bone implant comprising a multi-modal shape memory polymer material comprising a blend of at least a first polymer component having a first molecular weight and at least a second polymer component having a second molecular weight that is less than the first component, the first polymer component and the second polymer component being miscible, at least one of the first or second polymer components being non-resorbable, wherein if a bone implant so prepared is provided with energy and heated to a temperature higher than the glass transition temperature of the polymer, but lower than its melting temperature, the implant material will flow, and if inserted into bone, will flow into pores of the bone thereby implanting the implant into the bone.
  • 2. The method of claim 1, wherein the first molecular weight is in excess of about 50,000 Daltons and the second molecular weight is up to about 20,000 Daltons.
  • 3. The method of claim 1, wherein the first molecular weight is between about 50,000 and about 1,000,000 Daltons and the second molecular weight is between about 2,000 and about 30,000 Daltons.
  • 4. The method of claim 1, wherein the first polymer component comprises about 80% of the polymer blend and the second polymer component comprises about 20% of the polymer blend.
  • 5. The method of claim 2, wherein the first polymer component comprises about 80% of the polymer blend and the second polymer component comprises about 20% of the polymer blend.
  • 6. The method of claim 1, wherein the multi-modal shape memory polymer is bimodal, and the first polymer component and the second polymer component are both non-resorbable.
  • 7. The method of claim 1, wherein the implant further comprises reinforced polymeric material comprising a composite or matrix including reinforcing material or phases selected from the group consisting of glass fibers, carbon fibers, polymeric fibers, ceramic particulates, rods, platelets, and combinations thereof.
  • 8. The method of claim 1, wherein at least one or both of the at least one polymer component and the second polymer component includes a component selected from the group consisting of polyacrylates, polymethyl methacrylate polymers or copolymers thereof, polybutyl methacrylate polymers or copolymers thereof, polybutyl methacrylate-co-polymethyl methacrylate copolymers, polystyrene copolymers, and combinations thereof.
  • 9. The method of claim 1, wherein the article comprises active agents selected from the group consisting of bone morphogenic proteins, antibiotics, anti-inflammatories, angiogenic factors, osteogenic factors, monobutyrin, thrombin, modified proteins, platelet rich plasma, platelet rich solution, platelet poor plasma, platelet poor solution, bone marrow aspirate, and combinations thereof, and the active agent is incorporated into the polymeric shape memory material to be released during the relaxation and/or degradation of the polymer material.
  • 10. A method of manufacturing a bone implant that, if implanted and exposed to energy and heat, flows into surrounding bone enhancing implantation comprising: creating a desired bone implant comprising a multi-modal shape memory polymer material comprising a blend of at least a first polymer component having a first molecular weight and at least a second polymer component having a second molecular weight that is less than the first component, the first polymer component and the second polymer component being miscible, and at least one of the first or second polymer components being non-resorbable, wherein if the implant is inserted into bone and provided with energy and heat to a temperature higher than the glass transition temperature of the polymer, but lower than its melting temperature, the material flows into pores of the bone thereby enhancing implantation of the implant into the bone.
  • 11. The method of claim 10, wherein the first molecular weight is in excess of about 50,000 Daltons and the second molecular weight is up to about 20,000 Daltons.
  • 12. The method of claim 10, wherein the first molecular weight is between about 50,000 and about 1,000,000 Daltons and the second molecular weight is between about 2,000 and about 30,000 Daltons.
  • 13. The method of claim 10, wherein the first polymer component comprises about 80% of the polymer blend and the second polymer component comprises about 20% of the polymer blend.
  • 14. The method of claim 10, wherein the multi-modal shape memory polymer is bimodal, and the first polymer component and the second polymer component are both non-resorbable.
  • 15. The method of claim 10, wherein the implant is porous.
  • 16. The method of claim 10, wherein the implant further comprises reinforced polymeric material comprising a composite or matrix including reinforcing material or phases selected from the group consisting of glass fibers, carbon fibers, polymeric fibers, ceramic particulates, rods, platelets, and combinations thereof.
  • 17. The method of claim 10, wherein at least one or both of the at least one polymer component and the second polymer component includes a component selected from the group consisting of polyacrylates, polymethyl methacrylate polymers or copolymers thereof, polybutyl methacrylate polymers or copolymers thereof, polybutyl methacrylate-co-polymethyl methacrylate copolymers, polystyrene copolymers, and combinations thereof.
  • 18. The method of claim 10, wherein the article comprises active agents selected from the group consisting of bone morphogenic proteins, antibiotics, anti-inflammatories, angiogenic factors, osteogenic factors, monobutyrin, thrombin, modified proteins, platelet rich plasma, platelet rich solution, platelet poor plasma, platelet poor solution, bone marrow aspirate, and combinations thereof, and are incorporated into the polymeric shape memory material to be released during the relaxation and/or degradation of the polymer material.
  • 19. A method of implanting an article into bone comprising: implanting a bone implant article into a bone, the article comprising a multi-modal shape memory polymer material comprising a blend of at least a first polymer component having a first molecular weight and at least a second polymer component having a second molecular weight that is less than the first component, the first polymer component and the second polymer component being miscible, at least one of the first or second polymer components being non-resorbable, and wherein upon implanting the article into bone and providing the article with energy and heating to a temperature higher than the glass transition temperature of the polymer, but lower than its melting temperature, the material flows into pores of the bone thereby implanting the article into the bone.
  • 20. The method of claim 19, wherein at least one or both of the at least one polymer component and the second polymer component includes a component selected from the group consisting of polyacrylates, polymethyl methacrylate polymers or copolymers thereof, polybutyl methacrylate polymers or copolymers thereof, polybutyl methacrylate-co-polymethyl methacrylate copolymers, polystyrene copolymers, and combinations thereof.
  • 21. The method of claim 19, wherein the article comprises active agents selected from the group consisting of bone morphogenic proteins, antibiotics, anti-inflammatories, angiogenic factors, osteogenic factors, monobutyrin, thrombin, modified proteins, platelet rich plasma, platelet rich solution, platelet poor plasma, platelet poor solution, bone marrow aspirate, and combinations thereof, and are incorporated into the polymeric shape memory material to be released during the relaxation and/or degradation of the polymer material.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation application of U.S. application Ser. No. 12/595,341, filed Oct. 9, 2009, which claims the benefit of a Section 371 U.S. National Stage filing of PCT/US08/60783, filed Apr. 18, 2008, which claims the benefit of U.S. Provisional Application No. 60/912,827, filed Apr. 19, 2007, the entire contents of each which are hereby incorporated herein by reference.

US Referenced Citations (324)
Number Name Date Kind
3531561 Trehu Sep 1970 A
3636956 Schneider Jan 1972 A
3736646 Schmitt et al. Jun 1973 A
3797499 Schneider Mar 1974 A
3856905 Dawson Dec 1974 A
3926459 Pontigny Dec 1975 A
4137921 Okuzumi et al. Feb 1979 A
4181983 Kulkarni Jan 1980 A
4438253 Casey et al. Mar 1984 A
4523591 Kaplan et al. Jun 1985 A
4539981 Tunc Sep 1985 A
4559945 Koelmel et al. Dec 1985 A
4636215 Schwartz Jan 1987 A
4700704 Jamiolkowski et al. Oct 1987 A
4756307 Crowninshield Jul 1988 A
4916207 Boyle, Jr. et al. Apr 1990 A
4938763 Dunn et al. Jul 1990 A
4950258 Kawai et al. Aug 1990 A
4968317 Tormala et al. Nov 1990 A
4990161 Kampner Feb 1991 A
5049591 Hayashi et al. Sep 1991 A
5053035 McLaren Oct 1991 A
5061181 Niznick Oct 1991 A
5108289 Fukuyo Apr 1992 A
5108755 Daniels et al. Apr 1992 A
5110852 Gogolewski et al. May 1992 A
5192301 Kamiya et al. Mar 1993 A
5201771 Belykh et al. Apr 1993 A
5208305 Grootaert May 1993 A
5250584 Ikada et al. Oct 1993 A
5266608 Katz et al. Nov 1993 A
5275601 Gogolewski et al. Jan 1994 A
5294395 Broyer Mar 1994 A
5324308 Pierce Jun 1994 A
5333624 Tovey Aug 1994 A
5360448 Thramann Nov 1994 A
5364400 Rego, Jr. et al. Nov 1994 A
5376120 Sarver et al. Dec 1994 A
5383931 Hehli et al. Jan 1995 A
5407445 Tautvydas et al. Apr 1995 A
5417712 Whittaker et al. May 1995 A
5437918 Taniguchi et al. Aug 1995 A
5441515 Khosravi et al. Aug 1995 A
5458653 Davidson Oct 1995 A
5470334 Ross et al. Nov 1995 A
5525706 Gruber et al. Jun 1996 A
5527337 Stack et al. Jun 1996 A
5527341 Gogolewski et al. Jun 1996 A
5562704 Tamminmaki et al. Oct 1996 A
5567431 Vert et al. Oct 1996 A
5569250 Sarver et al. Oct 1996 A
5571193 Kampner Nov 1996 A
5571204 Nies Nov 1996 A
5633002 Stricker et al. May 1997 A
5634936 Linden et al. Jun 1997 A
5641502 Skalla et al. Jun 1997 A
5660846 Cheikh Aug 1997 A
5665831 Neuenschwander et al. Sep 1997 A
5670161 Healy et al. Sep 1997 A
5676699 Gogolewski et al. Oct 1997 A
5690671 McGurk et al. Nov 1997 A
5695497 Stahelin Dec 1997 A
5700901 Hurst et al. Dec 1997 A
5716410 Wang et al. Feb 1998 A
5716413 Walter et al. Feb 1998 A
5733330 Cox Mar 1998 A
5741329 Agrawal et al. Apr 1998 A
5760118 Sinclair et al. Jun 1998 A
5766239 Cox Jun 1998 A
5766618 Laurencin et al. Jun 1998 A
5792400 Talja et al. Aug 1998 A
5817328 Gresser et al. Oct 1998 A
5834582 Sinclair et al. Nov 1998 A
5837276 Cheikh Nov 1998 A
5853639 Kawakami et al. Dec 1998 A
5863297 Walter et al. Jan 1999 A
5868746 Sarver et al. Feb 1999 A
5893850 Cachia Apr 1999 A
5902599 Anseth et al. May 1999 A
5904658 Niederauer et al. May 1999 A
5908918 Chen et al. Jun 1999 A
5935172 Ochoa et al. Aug 1999 A
5939453 Heller et al. Aug 1999 A
5947893 Agrawal et al. Sep 1999 A
5951288 Sawa Sep 1999 A
5968092 Buscemi et al. Oct 1999 A
5977204 Boyan et al. Nov 1999 A
5980564 Stinson Nov 1999 A
5997580 Mastrorio et al. Dec 1999 A
5997582 Weiss Dec 1999 A
6001100 Sherman et al. Dec 1999 A
6001101 Augagneur et al. Dec 1999 A
6005161 Brekke et al. Dec 1999 A
6071982 Wise et al. Jun 2000 A
6077989 Kandel et al. Jun 2000 A
6113624 Bezwada et al. Sep 2000 A
6136369 Leitao et al. Oct 2000 A
6150497 Sastry et al. Nov 2000 A
6156842 Hoenig et al. Dec 2000 A
6160084 Langer et al. Dec 2000 A
6162225 Gertzman et al. Dec 2000 A
6168570 Ferrera Jan 2001 B1
6179842 Spotorno et al. Jan 2001 B1
6203573 Walter et al. Mar 2001 B1
6206883 Tunc Mar 2001 B1
6248108 Tormala et al. Jun 2001 B1
6248430 Toyoda et al. Jun 2001 B1
6277390 Schaffner Aug 2001 B1
6281262 Shikinami Aug 2001 B1
6283973 Hubbard et al. Sep 2001 B1
6293950 Lynch et al. Sep 2001 B1
6299448 Zdrahala et al. Oct 2001 B1
6303697 Yuan et al. Oct 2001 B1
6315788 Roby Nov 2001 B1
6344496 Niederauer et al. Feb 2002 B1
6375465 Engman et al. Apr 2002 B1
6388043 Langer et al. May 2002 B1
6406498 Tormala et al. Jun 2002 B1
6425923 Stalcup et al. Jul 2002 B1
6436136 Flodin et al. Aug 2002 B1
6447515 Meldrum Sep 2002 B1
6468277 Justin et al. Oct 2002 B1
6486296 Shimamoto et al. Nov 2002 B1
6488938 Ogura et al. Dec 2002 B1
6503278 Pohjonen et al. Jan 2003 B1
6508830 Steiner Jan 2003 B2
6511511 Slivka et al. Jan 2003 B1
6514286 Leatherbury et al. Feb 2003 B1
6547792 Tsuji et al. Apr 2003 B1
6565606 Bruce et al. May 2003 B1
6579533 Tormala et al. Jun 2003 B1
6583232 Brown Jun 2003 B1
6599323 Melican et al. Jul 2003 B2
6605090 Trieu et al. Aug 2003 B1
6613089 Estes et al. Sep 2003 B1
6623487 Goshert Sep 2003 B1
6652582 Stinson Nov 2003 B1
6716957 Tunc Apr 2004 B2
6719935 Tunc Apr 2004 B2
6720402 Langer et al. Apr 2004 B2
6726696 Houser et al. Apr 2004 B1
6758862 Berry et al. Jul 2004 B2
6758863 Estes et al. Jul 2004 B2
6783712 Slivka et al. Aug 2004 B2
6827743 Eisennann et al. Dec 2004 B2
6830575 Stenzel et al. Dec 2004 B2
6841111 Rickner et al. Jan 2005 B2
6843799 Bartlett Jan 2005 B2
6852825 Lendlein et al. Feb 2005 B2
6869445 Johnson Mar 2005 B1
6881766 Hain Apr 2005 B2
6902584 Kwan et al. Jun 2005 B2
6908466 Bonutti et al. Jun 2005 B1
6908624 Hossainy et al. Jun 2005 B2
6916321 TenHuisen et al. Jul 2005 B2
6951956 Yamane et al. Oct 2005 B2
6974862 Ringeisen et al. Dec 2005 B2
7012106 Yuan et al. Mar 2006 B2
7033603 Nelson et al. Apr 2006 B2
7192443 Solem et al. Mar 2007 B2
7208550 Mather et al. Apr 2007 B2
7214765 Ringeisen et al. May 2007 B2
7261716 Strobel et al. Aug 2007 B2
7261734 Gellman et al. Aug 2007 B2
7268205 Williams et al. Sep 2007 B2
7270813 Shimp et al. Sep 2007 B2
7285087 Moaddeb et al. Oct 2007 B2
7285130 Austin Oct 2007 B2
7314480 Eidenschink et al. Jan 2008 B2
7335375 Li et al. Feb 2008 B2
7378144 DeMeo et al. May 2008 B2
7455674 Rose Nov 2008 B2
7524891 Rose Apr 2009 B2
7553923 Williams Jun 2009 B2
8501215 Chen et al. Aug 2013 B2
20010012940 Tunc Aug 2001 A1
20010018614 Bianchi Aug 2001 A1
20020022588 Wilkie et al. Feb 2002 A1
20020029041 Hover et al. Mar 2002 A1
20020029043 Ahrens et al. Mar 2002 A1
20020071822 Uhrich Jun 2002 A1
20020082362 Brocchini et al. Jun 2002 A1
20020120348 Melican et al. Aug 2002 A1
20020138154 Li et al. Sep 2002 A1
20020143403 Vaidyanathan et al. Oct 2002 A1
20020150775 Ishikawa et al. Oct 2002 A1
20020160032 Long et al. Oct 2002 A1
20030045941 Lewallen Mar 2003 A1
20030055198 Langer et al. Mar 2003 A1
20030104031 Dumont et al. Jun 2003 A1
20030114937 Leatherbury et al. Jun 2003 A1
20030120280 Rolier et al. Jun 2003 A1
20030125745 Tseng et al. Jul 2003 A1
20030130742 Connelly et al. Jul 2003 A1
20030153971 Chandrasekaran Aug 2003 A1
20030153972 Helmus Aug 2003 A1
20030180344 Wise et al. Sep 2003 A1
20030236573 Evans et al. Dec 2003 A1
20040002770 King et al. Jan 2004 A1
20040015187 Lendein et al. Jan 2004 A1
20040019386 Ferree Jan 2004 A1
20040030341 Aeschlimann et al. Feb 2004 A1
20040030342 Trieu et al. Feb 2004 A1
20040052992 Boone et al. Mar 2004 A1
20040054372 Corden et al. Mar 2004 A1
20040106734 Rose Jun 2004 A1
20040109823 Kaplan Jun 2004 A1
20040110285 Lendlein et al. Jun 2004 A1
20040115239 Shastri et al. Jun 2004 A1
20040131681 Ambrose et al. Jul 2004 A1
20040143221 Shadduck Jul 2004 A1
20040153075 Roger Aug 2004 A1
20040156878 Rezania et al. Aug 2004 A1
20040172118 Gibson Sep 2004 A1
20040193154 Leatherbury et al. Sep 2004 A1
20040241203 Shakesheff et al. Dec 2004 A1
20040242722 Rose Dec 2004 A1
20040254639 Li et al. Dec 2004 A1
20040258732 Shikinami Dec 2004 A1
20040259972 Ringeisen et al. Dec 2004 A1
20040260398 Kelman Dec 2004 A1
20040265385 West Dec 2004 A1
20040267263 May Dec 2004 A1
20050008672 Winterbottom et al. Jan 2005 A1
20050013793 Beckman et al. Jan 2005 A1
20050019404 Sung et al. Jan 2005 A1
20050033295 Wisnwski Feb 2005 A1
20050043751 Phan et al. Feb 2005 A1
20050043752 Phan et al. Feb 2005 A1
20050070928 Heino et al. Mar 2005 A1
20050080483 Solem et al. Apr 2005 A1
20050080489 Estes et al. Apr 2005 A1
20050085313 Nishitani Apr 2005 A1
20050085812 Sherman et al. Apr 2005 A1
20050090861 Porter Apr 2005 A1
20050107886 Crabtree et al. May 2005 A1
20050123582 Sung et al. Jun 2005 A1
20050125051 Eidenschink et al. Jun 2005 A1
20050136764 Sherman et al. Jun 2005 A1
20050137611 Escudero et al. Jun 2005 A1
20050137715 Phan et al. Jun 2005 A1
20050159812 Dinger, III et al. Jul 2005 A1
20050165128 Cohn et al. Jul 2005 A1
20050177144 Phan et al. Aug 2005 A1
20050177245 Leatherbury et al. Aug 2005 A1
20050182411 DeMeo et al. Aug 2005 A1
20050182428 Bearinger et al. Aug 2005 A1
20050187602 Eidenschink et al. Aug 2005 A1
20050196420 Zucherman et al. Sep 2005 A1
20050197422 Mayadunne et al. Sep 2005 A1
20050208094 Armitage et al. Sep 2005 A1
20050209705 Niederauer et al. Sep 2005 A1
20050240281 Slivka et al. Oct 2005 A1
20050273106 Oepen Dec 2005 A1
20060027612 Boaron Feb 2006 A1
20060051394 Moore et al. Mar 2006 A1
20060067973 Schachter Mar 2006 A1
20060095138 Truckai et al. May 2006 A1
20060121084 Borden et al. Jun 2006 A1
20060121087 Williams et al. Jun 2006 A1
20060136071 Maspero et al. Jun 2006 A1
20060149248 Schlienger et al. Jul 2006 A1
20060177480 Sung et al. Aug 2006 A1
20060178748 Dinger, III et al. Aug 2006 A1
20060188546 Giroux Aug 2006 A1
20060188547 Bezwada Aug 2006 A1
20060200150 Ilomaki et al. Sep 2006 A1
20060247610 Lanphere et al. Nov 2006 A1
20060263335 France et al. Nov 2006 A1
20060264948 Williams Nov 2006 A1
20060293749 Hudgins et al. Dec 2006 A1
20070005094 Eaton et al. Jan 2007 A1
20070014831 Sung et al. Jan 2007 A1
20070041950 Leatherbury et al. Feb 2007 A1
20070043376 Leatherbury et al. Feb 2007 A1
20070043433 Chandrasekaran Feb 2007 A1
20070048383 Helmus Mar 2007 A1
20070050018 Wainwright Mar 2007 A1
20070065652 Liebschner Mar 2007 A1
20070067043 Dericks Mar 2007 A1
20070083205 Attawia et al. Apr 2007 A1
20070100449 O'Niel et al. May 2007 A1
20070128154 Hadba et al. Jun 2007 A1
20070134305 Zilberman Jun 2007 A1
20070141111 Zuokas et al. Jun 2007 A1
20070156251 Karmon Jul 2007 A1
20070162019 Burns et al. Jul 2007 A1
20070182041 Rizk et al. Aug 2007 A1
20070191963 Winterbottom et al. Aug 2007 A1
20070213828 Trieu et al. Sep 2007 A1
20070260324 Joshi et al. Nov 2007 A1
20070265622 Aeschlimann et al. Nov 2007 A1
20070270852 Tormala et al. Nov 2007 A1
20070276366 Gaines, Jr. Nov 2007 A1
20070280983 Strickler et al. Dec 2007 A1
20070299151 Gueicher et al. Dec 2007 A1
20070299156 Brown et al. Dec 2007 A1
20070299449 Allinniemi et al. Dec 2007 A1
20080015578 Erickson et al. Jan 2008 A1
20080077140 Osman Mar 2008 A1
20080085297 Dave et al. Apr 2008 A1
20080086199 Dave et al. Apr 2008 A1
20080109037 Steiner et al. May 2008 A1
20080154368 Justis et al. Jun 2008 A1
20080154373 Protopsaltis et al. Jun 2008 A1
20080200638 Redepenning Aug 2008 A1
20080206297 Roeder et al. Aug 2008 A1
20080228186 Gall et al. Sep 2008 A1
20080234754 McCarthy et al. Sep 2008 A1
20080234762 Forstein et al. Sep 2008 A1
20080241211 Han et al. Oct 2008 A1
20080249633 Wu Oct 2008 A1
20080262613 Gogolewski Oct 2008 A1
20080305144 Brown et al. Dec 2008 A1
20090030160 Kanazawa et al. Jan 2009 A1
20090048145 Hellerbrand et al. Feb 2009 A1
20090093888 Dawson et al. Apr 2009 A1
20090099600 Moore et al. Apr 2009 A1
20090149856 Paakinaho et al. Jun 2009 A1
20090170923 Gudmundsson Jul 2009 A1
20090171064 Arimura et al. Jul 2009 A1
20090204116 Shalaby et al. Aug 2009 A1
20090274742 Brown Nov 2009 A1
20100136648 Montes De Oca Balderas et al. Jun 2010 A1
Foreign Referenced Citations (133)
Number Date Country
1604403 Nov 1970 DE
2817778 Nov 1978 DE
2947985 Sep 1981 DE
3036611 Jun 1982 DE
3936188 May 1990 DE
4226465 Feb 1993 DE
4220216 Jan 1994 DE
102005032005 Jan 2007 DE
204931 Dec 1986 EP
299004 Jan 1989 EP
321389 Jun 1989 EP
326426 Aug 1989 EP
401844 Dec 1990 EP
404004 Dec 1990 EP
439892 Aug 1991 EP
475077 Mar 1992 EP
531487 Mar 1993 EP
590656 Apr 1994 EP
595956 May 1994 EP
635274 Jan 1995 EP
711534 May 1996 EP
747072 Dec 1996 EP
751165 Jan 1997 EP
803521 Oct 1997 EP
805175 Nov 1997 EP
806283 Nov 1997 EP
815809 Jan 1998 EP
1000958 May 2000 EP
1009448 Jun 2000 EP
1056487 Dec 2000 EP
1086711 Mar 2001 EP
1093774 Apr 2001 EP
1136510 Sep 2001 EP
1142597 Oct 2001 EP
1216717 Jun 2002 EP
1277482 Jan 2003 EP
1284756 Feb 2003 EP
2691901 Dec 1993 FR
2691991 Dec 1993 FR
2863478 Jun 2005 FR
807589 Jan 1959 GB
1416575 Dec 1975 GB
2215209 Sep 1989 GB
62-199429 Feb 1989 JP
2169612 Jun 1990 JP
10309313 Nov 1998 JP
01-192367 Jul 2001 JP
02-270519 Sep 2002 JP
03-021613 Jan 2003 JP
3053045 Feb 2003 JP
2003-094516 Apr 2003 JP
2003-518230 Jun 2003 JP
2006-503172 Jan 2006 JP
06-234157 Sep 2006 JP
2007046050 Feb 2007 JP
06-065460 Mar 2008 JP
8196617 Aug 2008 JP
9040761 Feb 2009 JP
9095606 May 2009 JP
9221539 Oct 2009 JP
9234241 Oct 2009 JP
09234241 Oct 2009 JP
9272790 Nov 2009 JP
10176039 Aug 2010 JP
11209595 Oct 2011 JP
05-147105 Feb 2013 JP
0180858 Apr 1999 KR
8404311 Nov 1984 WO
9003768 Apr 1990 WO
9301773 Feb 1993 WO
9534331 Dec 1995 WO
9622061 Jul 1996 WO
9705193 Feb 1997 WO
9725936 Jul 1997 WO
9729673 Aug 1997 WO
9736555 Oct 1997 WO
9800141 Jan 1998 WO
9826814 Jun 1998 WO
9830141 Jul 1998 WO
9847445 Oct 1998 WO
9911296 Mar 1999 WO
9911297 Mar 1999 WO
9922770 May 1999 WO
0001426 Jan 2000 WO
0056376 Sep 2000 WO
0146501 Jun 2001 WO
0196105 Dec 2001 WO
0200137 Jan 2002 WO
0234159 May 2002 WO
0234310 May 2002 WO
02076725 Oct 2002 WO
03004071 Jan 2003 WO
03057844 Jul 2003 WO
03064531 Aug 2003 WO
2004011054 Feb 2004 WO
2004071356 Aug 2004 WO
2004110313 Dec 2004 WO
2005014718 Feb 2005 WO
2005028534 Mar 2005 WO
2005046470 May 2005 WO
2005085313 Sep 2005 WO
2005112804 Dec 2005 WO
2006053936 May 2006 WO
2006064025 Jun 2006 WO
2006095138 Sep 2006 WO
2006108114 Oct 2006 WO
2006114483 Nov 2006 WO
2006116129 Nov 2006 WO
2007020430 Feb 2007 WO
2007020432 Feb 2007 WO
2007021593 Feb 2007 WO
WO 2007020430 Feb 2007 WO
2007023296 Mar 2007 WO
2007024492 Mar 2007 WO
2007038009 Apr 2007 WO
2007065074 Jun 2007 WO
2007084609 Jul 2007 WO
2007086832 Aug 2007 WO
2007111808 Oct 2007 WO
2007117499 Oct 2007 WO
2008001633 Jan 2008 WO
2008004011 Jan 2008 WO
2008044011 Apr 2008 WO
2008067561 Jun 2008 WO
2008089172 Jul 2008 WO
2008098019 Aug 2008 WO
2008101932 Aug 2008 WO
2008112875 Sep 2008 WO
2008112893 Sep 2008 WO
2008112912 Sep 2008 WO
2008116591 Oct 2008 WO
2008131197 Oct 2008 WO
2008134264 Nov 2008 WO
Non-Patent Literature Citations (101)
Entry
Office Action for Japanese Application No. 2010504268 dated Jan. 8, 2013,4 pages.
Japanese Office Action dated Jun. 19, 2012 for JP Application 2010-504182. p. 1-6.
Examination Report for counterpart Australian Application No. 2008242737 dated Aug. 10, 2012, pp. 1-3.
Atkins, G., Haynes, D.R., Howie, D.W., & Findlay, D.M., Role of polyethylene particles in peri-prosthetic osteolysis: A Review, World of Journals of Orthopedics, 2(10), Oct. 18, 2011, pp. 93-101.
Hill, R.G., “Biomedical Polymers: Biomaterials, artificial organs and tissue engineering”, Imperial College London, UK, date unknown but prior to the date of this application, 7 pages.
Vert, M., Li, S.M., Spenlehaur, G., Guerin, P., “Pioresorbability and biocompatibility of aliphatic polyesters”, Journal of Materials Science: Materials in Medicine 3, 1992, pp. 432-446.
English Translation, Decision to Reject the Amendments, and Decision of Rejection for Japanese Patent Application No. 2010-504268 dated Oct. 1, 2013,11 pages.
Steen dam, et ai. The role of elastic relaxation in drug delivery from poly(DL-lactic acid) based tablets. A shape memory phenomenon: Proceedings of the International Symposium on Controlled Release of Bioactive Materials, 25:128-129 (1998).
Stevels, et ai., “Blends can clok copolumeren die een poly(L-lactide) ofpoly(D-ladtide) blok bevatten”, Biomedical Science and Engineering Meeting, pp. 107-110 (1994).
Structure and Properties of Oriented Polymers, Ed. I. M. Ward, Department of Physics, University of Leads, England, a Halsted Press Book, John Wiley & Sons, New York-Toronto (1975) Table of Contents.
Summary of the Office Action, dated Mar. 19, 2012, 1 page. Tagl, “These—The morselized and impacted bone graft animal experiments on proteins, impaction and load”, Acta Orthop. Scan. Suppi., 290:1-40 (2000).
Temenoff, et ai., “Injectable biodegradable materials for orthopedic tissue engineering”, Biomaterials, 21:2405-2412 (2000).
Tschakaloff, et ai., “Degradation kinetics of biodegradable DL-polyactic acid biodegradable implants depending on the site of implantation”, International Journal of Oral and Maxillofacial Surgery, 23(6):443-445 (1994).
Tsuji, et ai., Stereocomplex formation between enantiomeric poly(lactic acid). VIII. Complex Fibers spun from mixed solution of poly(D-lactic acid) and poly(L-lactic acid), Journal of Applied Polymer Science, 51(2):337-344 (1994).
West, J., “Bioactive Polymers, Synthetic biodegradable polymer scaffolds”, Chapter 5, pp. 83-95, Anthony Atala and David J. Mooney, Editors; Joseph P. Vacanti and Robert Langer, Associate Editors, Birkhauser (1997).
Zegula, et ai. “Bone Formation with Use ofrhBMP-2 (Recombinant Human Bone Morphogenetic Protein-2”, The Journal of Bone and Joint Surgery, 79: 1778-1790 (1997).
Zhang, Biodegradable lactide polmers: synthesis, degradation, and controlled drug release properties ( drug release), Queen's University at Kingston, canada, vol. 55/01-B of Dissertation Abstracts International, p. i-xv, 1-179 (Oct. 1993).
International Search Report and Written Opinion for PCTIUS20081 060783 dated Jul. 23, 2008.
International Preliminary Report on Patentability and Written Opinion for PCT Application No. PCT/GB2012/052478 dated Apr. 8, 2014, 14 pages.
International Search Report for PCT Application No. PCT/GB20121 052478 dated Jun. 20, 2013, 5 pages.
International Preliminary Report on Patentability and Written Opinion for PCT Application No. dated Apr. 8, 2014,6 pages.
International Search Report for PCT Patent Application No. PCTI GB20121052470 dated Feb. 22, 2013, 2 pages.
International Search Report for PCT Application No. PCT/GB20121 052475 dated Mar. 8, 2013, 3 pages.
International Search Report and Written Opinion for PCT Application No. PCT/GB20121052475 dated Apr. 8, 2014,10 pages.
International Preliminary Report on Patentability and Written Opinion for PCT Application No. PCT/GB20121052480 dated Apr. 8, 2014, 12 pages.
International Search Report for PCT Application No. PCT/GB20121 052480 dated May 31, 2013,4 pages.
International Search Report and Written Opinion for PCTIUS20081 060783 dated Jul. 23, 2008, 2 pages.
Andriano et ai., “Processing and characterization of absorbable polyactidepolymers for use in surgical implants”, Journal of Applied Biomaterials, 5(2):133-140 (1994).
Barca et ai., “Resorbable poly-L-lactic acid in mini-staples of the fixation of Akin osteotomies”, The Journal of Foot and Ankle Surgery, 36(2) 106-111 (1997).
Bartenev et ai., On the theory of biaxial orientation of amorphous polymers, Mechanics of Composite Materials, 1973, co. 6, p. 671-677.
Bertrand et ai., “Biocompatibility Aspects of New Stent Technology”, JACC, 32(3):562-571 (1998).
Celikkaya et ai., “Poly(DL-lactide )Poly( ethylene glycol) Copolymer Particles. I preparation and Characterization”, Journal of Applied Polymer Science, 61: 1439-1446 (1996).
D. Hull and T.W. Clyne, “An introduction to composite materials,” Second Edition, Cambridge University Press, Table of Contents, (1996), 8 pages.
D. Wheeler et ai., “Effect ofbioactive glass particle size on osseous regeneration of cancellous defects”, J. Biomed. Materials Research, 41(4):527-533 (1998).
Daniels et ai., “Mechanical properties ofbiodegrabable polymers and compisites proposed for internal fixation of bone,”J. Applied Biomaterials, 1:57-78 (1990).
Biomaterials, 1:57-78 (1990).
Dauner et ai., “Resorbable continuous-fiber polymers for osteosynthesis”, J Materials Science Materials in Medicine, 9: 173-179 (1998).
Eling, et ai., “Biodegradable Materials of poly (I-lactic acid): 1. MeltSpun and Solution-Spun Fibres”, Polymer, 23: 1587-1593 (1982).
First Japanese Office Action for Application No. 2010-503579 dated Mar. 6, 2012, 6 pages.
First Office Action for Patent Application No. JP 2010-504201, mail dated Mar. 19, 2013, 5 pages.
Frenger, “Biomedical Uses of Shape Memory Polymers”, Miomed. Sci. Instrum., 29:47-50 (1993).
Fukuzaki et ai., Synthesis of copoly(D, L-Lactic acid) with relatively low molecular weight and in vitro degradation, Japan Atomic Energy Research Institute, Gunma, Jpn, European Polymer Journal, 25(10): 1019-1026 (1989).
Gautier et ai., “Synthesis of copoly(a-hydroxyacids) for application in the spinal cord: Resorbability and biocompatibility with adult rate Schwann cells and spinal cord”, Journal of Biomedican materials Research, 42(4):642-654 (1998).
Giardino et ai., “Experiemental evaluation of a resorbable intramedullary plug for cemented total hip replacement”, Biomaterials, 18(13)907-913 (1997).
Gogolewski et ai., “Resorbable materials ofpoly(L-lactide). II Fibers spun from solutions of poly(L-lactide) in good solvents”, J Appi. Polymer Sci., 28:1045-1061, (1983).
Grijpma et ai., “Chain Entanglement Mechanical Properties and Drawability of Poly (Lactide )”, Colloid Polym Sci., 272: 1068-1081 (1994).
Haers et al., “Biodegradable polyactide plates and screws in othognathic surgery”, Technical Note, Journal of Cranio-Maxillofacial Surgery, 26(2):87-91 (1998).
Hench, L.L., “Bioactive materials: The potential for tissue regeneration”, J. Biomed. Materials Research, 41(4):511-518 (1998).
Hyon et al., “Effects of residual monomer on the degradation of DL-lactide polymer”, Hyon, Jamshidi & Ikada, Polymer International, 46: 196-202 (1998).
International Search Report and Written Opinion for PCT/GB20081 001331 dated Aug. 25, 2008.
Water Transport in Polylactic Acid (PLA), Siparsky et al. Journal of Enviornmental Polymer Degradation, vol. 5, No. 3, 1997.
Andriano, et al., ‘Processing and characterization of absorbable polulactide polumers for use in surgical implants,’ Journal of Applied Biomaterials, 5(2):133-140 (1994).
Assano, et al., ‘In vivo characteristics of low molecular weight copoly (D.L-lactic acid) formulations with controlled release of LH-RH agonist,’ Biomaterials, 10(8):569-573 (1989).
Barca, et al., ‘Resorbable poly-L-lactic acid mini-staplesfor the fixation of Akin osteotomies,’ The Hournal of Foot and Ankle Surgery, 36(2):106-111 (1997).
Bartenev, et al., On the theory of biaxial orientation of amorphous polymers, Mechanics of Composite Materials, 1973, vol. 6, p. 671-677.
Bertrand, et al., Biocompatibility Aspects of New Stent Technology, JACC, 32(3):562-571 (1998).
Celikkaya, et al., ‘Poly(DL-lactide)/Poly(ethylene glycol) Copolymer Particles. I. Preparation and Characterization’, Journal of Applied Polymer Science, 61:1439-1446 (1996).
D. Hull and T.W. Clyne,‘An introduction to composite materials,’ Second Edition, Cambridge University Press, Table of Contents, (1996), 8 pages.
D. Wheeler, et al., ‘Effect of bioactive glass particle size on osseous regeneration of cancellous defects,’ J Biomed. Materials Research, 41(4):527-533 (1998).
Daniels, et al.,‘Mechanical properties of biodegradable polymers and composites proposed for internal fixation of bone,’ J. Applied Biomaterials, 1:57-78 (1990).
Dauner, et al.,‘Resorbable continuous-fiber reinforced polymers for osteosynthesis,’ J. Materials Science Materials and Medicine, 9:173-179 (1998).
Eling, et al.,‘Biodegradable Materials of Poly(L-Lactic Acid): 1. Melt-Spun and Solution-Spun Fibres,’ Polymer, 23:1587-1593 (1982).
Fambri, et ai., ‘Biodegradable fibres of poly (I-lactic acid) produced by melt spinning,’ Polymer, 38:79-85 (1997). Frenger, ‘Biomedical Uses of Shape Memory Polymers,’ Biomed. Sci. Instrum., 29:47-50 (1993).
Fukuzaki, et ai., Synthesis of copoly(D,L-Lactic acid) with relatively low molecular weight and in vitro degradation, Japan Atomic Energy Research Institute, Gunma, Jpn, European Polymer Journal, 25(10):1019-1026 (1989).
Gautier, et al., ‘Poly(a-hydroxyacids) for application in the spinal cord: Resorbability and biocompatibility with adult rate Schwann cells and spinal cord,’ Journal of Biomedical Materials Research, 42(4):642-654 (1998).
Giardino, et al., ‘Experimental evaluation of a resorbable intramedullary plug for cemented total hip replacement,’ Biomaterials, 18(13):907-913 (1997).
Gogolewsji, et ai., ‘Resorbable materials of poly(L-lactide). II Fibers spun from solutions of poly(L-lactide) in good solvents,’ J. Appi. Polymer Sci., 28:1045-1061 (1983).
Grijpma et ai., ‘Chain Entanglement Mechanical Properties and Drawability of Poly (Lactide ),’ Colloid Polym Sci., 272: 1068-1081 (1994).
Haers, et ai., ‘Biodegradable polyactide plates and screws in orthognathic surgery,’ Technical Note, Journal of Cranio-Maxillofacial Surgery, 26(2):87-91 (1998).
Hyon, et ai., ‘Effects of residual monomer on the degradation of DL-lactide polymer,’ Hyon, Jamshidi & Ikeda, Polymer International, 46: 196-202 (1998).
J. West et ai, ‘Bioactive Polymers, Synthetic biodegradable polymer scaffolds,’ Chapter 5, pp. 83-95, Anthony Atalaand DavidJ. Mooney, Editors; Joseph P. Vacanti and Robert Langer, Associate Editors, Birkhauser (1997).
Kaitian, et ai., ‘Poly(D,L-Lactic Acid) Homopolymers: Synthesis and Characterization,’ Turkish Journal of Chemistry, 20:43-53 (1996).
Kister, et ai., ‘Effects of morphology, conformation and configuration on the IR and Raman spectra of various poly (lactic acid)s,’ Polymer, 39(2): 267-273 (1998).
Koelling, et al., ‘In vitro real-time aging and characterization of poly(LID-lactic acid),’ Proceedings of the 1997 Iffh Southern Biomedical Engineering Conference ( Cat. No. 97TH8270), pp. 197-201.
Kontio, et ai., ‘Fibrous wound repair associated with biodegradable poly-LiD-lactide copolymers implants: study of the expression of tenascin and cellular fibronectin,’ Journal of Materials Science—Materials in Medicine, 9: 10:603-609 (1988).
Kricheldorf, et ai., ‘Polyactones: 32. High-molecular weight polylactides by ring-opening polymerization with dibutylmagnesium or butylmagnesium chloride,’ Polymer, 36(15):2995-3003 (1995).
L. L. Hench, ‘Bioactive materials: The potential for tissue regeneration,’ J. Biomed. Materials Research, 41(4):511-518 (1998). Losken, et ai., ‘Memory ofDL-polylactic acid biodegradable plates,’ Ann. Plast. Surg., 32(6):606-611 (1994).
MacDonald, et al., ‘Enzymatic degradability of poly(lactide): Effects of chain stereochemistry and material crystallinity,’ Macromolecules, 29(23):7356-7361 (1996).
Mainil-Varlet, et al., ‘Effect of in vivo and in vitro degradation on molecular and mechanical properties of various low-molecular weight polylactides,’ Journal of Biomedical Materials Research, 36(3):360-380 (1997).
Matsumura, et ai., ‘Novel ring opening polymerization oflactide by lipase,’ Macromoi. Symp., 130:285-304 (1998).
Mauduit, J. et ai.; “Hydrolytic degradation of films prepared from blends of high and low molecular weight poly (DL lactic acid)s” Journal of Biomedical Materials Research, 1996, vol. 30, p. 201-207.
Morita, et ai., ‘Intravitreous delivery of dexamethasone sodium m-sulfobenzoate from poly(DL-lactic acid)implants,’ Biological & Pharmaceutical Bulletin, 21 (2): 188-190 (1998).
Okihara, et ai., Crystal structure of stereo complex of poly(L-lactide) and poly(D-lactide), Journal of Macromolecular Science-Physics, B30(1 and 2): 119-140 (1991).
Okuzaki, et ai., Mechanical Properties and Structure of the ZoneDrawn Poly(I-lactic acid) Fibers, Journal of Polymer Science, Part B, Polymer Physics, 37:991-996 (1999).
Oriented Polymer Materials, Edited by Stoyko Fakirov, published by Huthig & WepfVerlag Zug, Heidelberg, Oxford CTIUSA, Table of Contents pp. v, viii, ix-xix (1996).
Penning, et al., ‘Preparation and properties of absorbable fibres from I-lactide copolymers,’ Polymer, 34(5):942-951 (1993).
Pitt, et ai., ‘Modification of the rates of chain cleavage of polY(ecaprolactone) and related polyesters in the solid state,’ Journal of Controlled Release, 4:283-292 (1987).
Pitto, et ai., “Comparison of fixation of the femoral component without cement and fixation with use of a bone-vacuum cementing technique for the prevention of fat embolism during total hip arthroplasty,” J. Bone Joint Surg., 81-A (6)-831-843 (1999).
Rak, et al., ‘The preparation and characterization ofpoly(D,L-lactic acid) for use as a biodegradable drug carrier,’ (1985) liverpool Poly tech., liverpool, UK, Pharmaceutic a Acta Helvetiae, 60:(5-6):162-169.
Ristic, et ai., ‘An investigation of synthesis and degradation of poly(D,L-lactide) and controlled release of albumin from biodegradable poly(D,L-lactide) cylinders,’ ICheaP-2, the second Italian conference on chemical and process engineering, Florence, pp. 559-563 (1995).
Schliephake, et ai., ‘Reconstruction of the mandible by prefabricated autogenous bone grafts,’ Int. J. Oral Maxillofac. Surg., 26:244-252 (1997).
Stahelin, et al., Clinical degradation and biocompatibility of different bioabsorbable interference screws: a report of six cases: Arthroscopy: The Journal of Arthroscopic & Related Surgery, 13(2):238-244 (1997).
Steendam, et ai., The role of elastic relaxation in drug delivery from poly(DL-lactic acid) based tablets. A shape memory phenomenon: Proceedings of the International Symposium on Controlled Release of Bioactive Materials, 25:128-129 (1998).
Stevels, et ai., ‘Blends van blok copolymeren die een poly(L-lactide) of poly(D-lactide) blok bevatten,’ Biomedical Science and Engineering Meeting, pp. 107-110 (1994).
Tagl, “Thesis—The morselized and impacted bone graft animal experiments on proteins, impaction and load,” Acta Orthop. Scand. Suppi., 290:1-40 (2000).
Temenoff et ai., “Injectable biodegradable materials for orthopedic tissue engineering,” Biomaterials, 21 :2405-2412 (2000).
Tschakaloff, et ai., ‘Degradation kinetics of biodegradable DL-polyactic acid biodegradable implants depending on the site of implantation,’ International Journal of Oral and Maxillofacial Surgery, 23(6 Pt2 ):443-445 (1994).
Zegzula, et ai., ‘Bone Formation with Use of rhBMP-2 (Recombinant Human Bone Morphogenetic Protein-2,’ The Journal of Bone and Joint Surgery, 79: 1778-1790 (1997).
Zhang, Biodegradable lactide polymers: synthesis, degradation, and controlled drug release properties (drug release), Queen's University at Kingston, Canada, vol. 55/01-B of Dissertation Abstracts International, p. i-xv, 1-179 (Oct. 1993).
Office Action for Japanese Application No. 2010504268 dated Jul. 17, 2012,6 pages.
Farnbri, et ai., “Biodegradable fibres of poly (I-lactic acid) produced by melt spinning”, Polymer, 38: 79-85 (1997).
Related Publications (1)
Number Date Country
20150151023 A1 Jun 2015 US
Provisional Applications (1)
Number Date Country
60912827 Apr 2007 US
Continuations (1)
Number Date Country
Parent 12595341 US
Child 14615322 US